- Home
- NCI vs BCTX Comparison
NCI vs BCTX Comparison
Compare NCI & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCI
- BCTX
- Stock Information
- Founded
- NCI 1992
- BCTX 2014
- Country
- NCI Hong Kong
- BCTX Canada
- Employees
- NCI N/A
- BCTX N/A
- Industry
- NCI
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- NCI
- BCTX Health Care
- Exchange
- NCI NYSE
- BCTX Nasdaq
- Market Cap
- NCI 15.2M
- BCTX 17.2M
- IPO Year
- NCI 2024
- BCTX N/A
- Fundamental
- Price
- NCI $0.58
- BCTX $0.79
- Analyst Decision
- NCI
- BCTX Strong Buy
- Analyst Count
- NCI 0
- BCTX 1
- Target Price
- NCI N/A
- BCTX $15.00
- AVG Volume (30 Days)
- NCI 436.1K
- BCTX 690.7K
- Earning Date
- NCI 12-03-2024
- BCTX 12-12-2024
- Dividend Yield
- NCI N/A
- BCTX N/A
- EPS Growth
- NCI N/A
- BCTX N/A
- EPS
- NCI 0.03
- BCTX N/A
- Revenue
- NCI $22,299,792.00
- BCTX N/A
- Revenue This Year
- NCI N/A
- BCTX N/A
- Revenue Next Year
- NCI N/A
- BCTX N/A
- P/E Ratio
- NCI $19.97
- BCTX N/A
- Revenue Growth
- NCI N/A
- BCTX N/A
- 52 Week Low
- NCI $0.35
- BCTX $0.46
- 52 Week High
- NCI $11.39
- BCTX $5.97
- Technical
- Relative Strength Index (RSI)
- NCI N/A
- BCTX 55.70
- Support Level
- NCI N/A
- BCTX $0.57
- Resistance Level
- NCI N/A
- BCTX $0.74
- Average True Range (ATR)
- NCI 0.00
- BCTX 0.06
- MACD
- NCI 0.00
- BCTX 0.00
- Stochastic Oscillator
- NCI 0.00
- BCTX 88.08
About NCI NEO-CONCEPT INTL GRP HLDGS LTD
Neo-Concept International Group Holdings Ltd is a company whose a one-stop apparel solution services provider. It offers a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management serving customers located in the European, and North American markets through Neo-Concept HK.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.